miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Lee, Yee Ming ^a,b   Lee, Jen Yi ^a,b   Ho, Chao Chi ^b   Hong, Qi Sheng ^b   Yu, Sung Liang ^b   Tzeng, Chii Ruey ^c   Yang, Pan Chyr ^b   Chen, Huei Wen ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; JAGGED1; LUCIFERASE; MICRORNA; MICRORNA 34B; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZERANOL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CALCIUM BINDING PROTEIN; ESTROGEN RECEPTOR; MEMBRANE PROTEIN; MIRN34 MICRORNA, HUMAN; SERRATE PROTEINS; SIGNAL PEPTIDE; TAMOXIFEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENDOMETRIUM CELL; ESTROGEN ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CELL; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CANCER STAGING; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; ESTROGENS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICE, SCID; MICRORNAS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81555235150     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3059     Document Type: Article

References (48)

1. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:1979-1987. 10.1158/1078-0432.CCR-09-1823, 20332324.
2. Ohshiro K, Kumar R. Evolving pathway-driven biomarkers in breast cancer. Expert Opin Investig Drugs 2010, 19(Suppl 1):S51-S56.
3. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol 2010, 28:3366-3379. 10.1200/JCO.2009.25.4011, 20530283.
4. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010, 120:293-308. 10.1007/s10549-010-0746-x, 20107892.
5. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002, 2:101-112. 10.1038/nrc721, 12635173.
6. Zwart W, Theodorou V, Carroll JS. Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdiscip Rev Syst Biol Med 2011, 3:216-230. 10.1002/wsbm.109, 21305704.
7. Rana A, Rangasamy V, Mishra R. How estrogen fuels breast cancer. Future Oncol 2010, 6:1369-1371. 10.2217/fon.10.112, 20919821.
8. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005, 19:833-842. 10.1210/me.2004-0486, 15695368.
9. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 2006, 7:497-508. 10.2174/138920206779315737, 2269003, 18369406.
10. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 2007, 7:713-722. 10.1038/nrc2211, 17721435.
11. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431:343-349. 10.1038/nature02873, 15372041.
12. Esquela-Kerscher A, Slack FJ. Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269. 10.1038/nrc1840, 16557279.
13. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010, 12:201. 10.1186/bcr2484, 2879559, 20346098.
14. Verghese ET, Hanby AM, Speirs V, Hughes TA. Small is beautiful: microRNAs and breast cancer: where are we now?. J Pathol 2008, 215:214-221. 10.1002/path.2359, 18446835.
15. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134. 10.1038/nature05939, 17554337.
16. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007, 67:8433-8438. 10.1158/0008-5472.CAN-07-1585, 17823410.
17. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network: another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007, 7:819-822. 10.1038/nrc2232, 17914404.
18. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T. Epigenetic silencing of MicroRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008, 68:4123-4132. 10.1158/0008-5472.CAN-08-0325, 18519671.
19. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18:1427-1431. 10.1093/bioinformatics/18.11.1427, 12424112.
20. Das PM, Ramachandran K, vanWert J, Singal R. Chromatin immunoprecipitation assay. Biotechniques 2004, 37:961-969.
21. González L, Agulló-Ortuño MT, García-Martínez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martín-Pérez J. Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 2006, 281:20851-20864. 10.1074/jbc.M601570200, 16728403.
22. Golubovskaya VM, Zheng M, Zhang L, Li JL, Cance WG. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 2009, 9:280. 10.1186/1471-2407-9-280, 3087335, 19671193.
23. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007, 67:11099-11101. 10.1158/0008-5472.CAN-07-2672, 18056431.
24. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008, 8:266. 10.1186/1471-2407-8-266, 2564978, 18803879.
25. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 2008, 7:1288-1296. 10.4161/cbt.7.8.6284, 18497571.
26. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993, 8:2127-2133.
27. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005, 65:8530-8537. 10.1158/0008-5472.CAN-05-1069, 16166334.
28. Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, Pan JG, Dering J, Reedijk M. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat 2009, 123:113-124.
29. Liu W, Ip MM, Podgorsak MB, Das GM. Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Res Treat 2009, 115:43-50. 10.1007/s10549-008-0044-z, 18481172.
30. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. Estrogen receptor α inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 2007, 67:7746-7755. 10.1158/0008-5472.CAN-06-3724, 17699779.
31. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM, Rajasekaran AK, Das GM. Estrogen receptor-α binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006, 281:9837-9840. 10.1074/jbc.C600001200, 16469747.
32. Li S, Hursting SD, Davis BJ, McLachlan JA, Barrett JC. Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Ann N Y Acad Sci 2003, 983:161-169. 10.1111/j.1749-6632.2003.tb05971.x, 12724221.
33. Götz F, Thieme S, Dörner G. Female infertility: effect of perinatal xenoestrogen exposure on reproductive functions in animals and humans. Folia Histochem Cytobiol 2001, 39(Suppl 2):40-43.
34. Liu S, Lin YC. Transformation of MCF-10A human breast epithelial cells by zeranol and estradiol-17β. Breast J 2004, 10:514-521. 10.1111/j.1075-122X.2004.21410.x, 15569208.
35. Quick EL, Parry EM, Parry JM. Do oestrogens induce chromosome specific aneuploidy in vitro, similar to the pattern of aneuploidy seen in breast cancer?. Mutat Res 2008, 651:46-55.
36. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010, 7:683-692. 10.1038/nrclinonc.2010.154, 20877296.
37. Burga LN, Hu H, Juvekar A, Tung NM, Troyan SL, Hofstatter EW, Wulf GM. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res 2011, 13:R30. 10.1186/bcr2850, 3219192, 21396117.
38. Boominathan L. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev 2010, 29:613-639. 10.1007/s10555-010-9257-9, 20922462.
39. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752. 10.1016/j.molcel.2007.05.010, 1939978, 17540599.
40. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008, 105:13556-13561. 10.1073/pnas.0803055105, 2528872, 18768788.
41. Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 2007, 6:1455-1459.
42. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007, 7:46-53. 10.1038/nrc2048, 17186017.
43. Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 2006, 13:1017-1026. 10.1038/sj.cdd.4401913, 16557268.
44. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995, 1:1029-1034. 10.1038/nm1095-1029, 7489358.
45. Vousden KH, Prives C. p53 and prognosis: new insights and further complexity. Cell 2005, 120:7-10.
46. Brown K. Is tamoxifen a genotoxic carcinogen in women?. Mutagenesis 2009, 24:391-404. 10.1093/mutage/gep022, 19505894.
47. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006, 15:718-727. 10.1016/j.breast.2006.02.005, 16675218.
48. Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, O'Malley FP, Egan SE, Andrulis IL. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 2008, 111:439-448. 10.1007/s10549-007-9805-3, 17990101.